183 related articles for article (PubMed ID: 38206518)
1. Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
Tarsia M; Vitale A; Gaggiano C; Sota J; Maselli A; Bellantonio C; Guerriero S; Dammacco R; La Torre F; Ragab G; Hegazy MT; Fonollosa A; Paroli MP; Del Giudice E; Maggio MC; Cattalini M; Fotis L; Conti G; Mauro A; Civino A; Diomeda F; de-la-Torre A; Cifuentes-González C; Tharwat S; Hernández-Rodríguez J; Gómez-Caverzaschi V; Pelegrín L; Babu K; Gupta V; Minoia F; Ruscitti P; Costi S; Breda L; La Bella S; Conforti A; Mazzei MA; Carreño E; Amin RH; Grosso S; Frediani B; Tosi GM; Balistreri A; Cantarini L; Fabiani C
Ophthalmol Ther; 2024 Mar; 13(3):761-774. PubMed ID: 38206518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry.
Vitale A; Casa FD; Guerriero S; Ragab G; Mauro A; Caggiano V; Cattalini M; Del Giudice E; Favale R; Gaggiano C; Bellicini I; Paroli MP; Hegazy MT; Sota J; Tufan A; Balistreri A; Almaghlouth I; La Torre F; Więsik-Szewczyk E; Tarsia M; Hinojosa-Azaola A; Martín-Nares E; Frediani B; Tosi GM; Fonollosa A; Hernández-Rodríguez J; Amin RH; Lopalco G; Rigante D; Cantarini L; Fabiani C
Ophthalmol Ther; 2023 Aug; 12(4):1957-1971. PubMed ID: 37166627
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience.
Sota J; Gentileschi S; Vitale A; Gaggiano C; De Bartolo G; Bianco MT; Frediani B; Tosi GM; Cantarini L; Fabiani C
Asia Pac J Ophthalmol (Phila); 2021 Mar; 10(4):360-365. PubMed ID: 33756492
[TBL] [Abstract][Full Text] [Related]
4. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis.
Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G
Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
6. The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors.
Fabiani C; Vitale A; Emmi G; Sgheri A; Lopalco G; Sota J; Guerriero S; Iannone F; Frediani B; Vannozzi L; Bianco MT; Giovannini V; Tosi GM; Cantarini L
Front Pharmacol; 2019; 10():1468. PubMed ID: 31920658
[No Abstract] [Full Text] [Related]
7. Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders.
Sota J; Guerriero S; Lopalco G; Tufan A; Ragab G; AlMaglouth I; Govoni M; Sfikakis PP; Frassi M; Vitale A; Kardas RC; Triggianese P; Chimenti MS; Aboabat AA; Piga M; Monti S; Sebastiani GD; Yildirim D; Conforti A; Gentileschi S; Dammacco R; Hinojosa-Azaola A; Kawakami-Campos PA; Ruffilli F; Torres-Ruiz J; Thabet M; Atig A; Ruscitti P; Cataldi G; Viapiana O; Hatemi G; Karakoç A; Costi S; Iagnocco A; Crisafulli F; Fragoulis G; Del Giudice E; Hegazy MT; Paroli MP; Şahin A; Morrone M; Iannone F; Opris-Belinski D; Asfina KN; Barone P; Gaggiano C; Kucuk H; Gicchino MF; Carubbi F; Caggiano V; Laskari K; Tharwat S; Direskeneli H; Alibaz-Oner F; Sevik G; Maier A; Laymouna AH; Emmi G; Akkoç N; Tarsia M; Sbalchiero J; Conti G; Spinella R; La Torre F; Tombetti E; Amin RH; Mauro A; Karamanakos A; Carreño E; Fonollosa A; Cattalini M; Breda L; de-la-Torre A; Wiesik-Szewczyk E; Cifuentes-González C; Ozen S; Mazzei MA; Tosi GM; Frediani B; Balistreri A; Batu ED; Gupta V; Cantarini L; Fabiani C
Ocul Immunol Inflamm; 2024 May; ():1-8. PubMed ID: 38759215
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.
Sözeri B; Kardeş E; Salı E; Çakır D; Demir F
Clin Exp Rheumatol; 2021; 39(4):907-912. PubMed ID: 33635217
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation.
Evereklioglu C; Sonmez HK; Sevim DG; Arda H; Sener H; Polat OA; Horozoglu F
Int Ophthalmol; 2023 Dec; 43(12):4461-4472. PubMed ID: 37555889
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis.
Tosi GM; Sota J; Vitale A; Rigante D; Emmi G; Lopalco G; Guerriero S; Orlando I; Iannone F; Frediani B; Angotti R; Messina M; Galeazzi M; Vannozzi L; Cantarini L; Fabiani C
Clin Exp Rheumatol; 2019; 37(4):680-683. PubMed ID: 30943133
[TBL] [Abstract][Full Text] [Related]
13. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
Dipasquale V; Pellegrino S; Ventimiglia M; Cucinotta U; Citrano M; Graziano F; Cappello M; Busacca A; Orlando A; Accomando S; Romano C;
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1007-1014. PubMed ID: 35830365
[TBL] [Abstract][Full Text] [Related]
15. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
[No Abstract] [Full Text] [Related]
16. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
17. Long-term Experience with Anti-tumor Necrosis factor- α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis.
Corredores Dieb J; Vofo B; Amer R
Ocul Immunol Inflamm; 2022 Dec; ():1-8. PubMed ID: 36538811
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Biosimilar Adalimumab in the Treatment of Behçet's Uveitis.
Soheilian M; Ebrahimiadib N; Hedayatfar A; Hosseini M; Zarei M; Anjidani N
Ocul Immunol Inflamm; 2022 Aug; 30(6):1495-1500. PubMed ID: 33826486
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.
Çam F; Celiker H
Eye (Lond); 2024 Apr; 38(5):893-901. PubMed ID: 37884704
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
Barry RJ; Tallouzi MO; Bucknall N; Mathers JM; Murray PI; Calvert MJ; Moore DJ; Denniston AK
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012577. PubMed ID: 30562409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
